Europe approves Tasigna for first-line CML
This article was originally published in Scrip
Executive Summary
Novartis completed the full set of major market approvals just before the Christmas break when the European Commission gave the green light to the Swiss major's Tasigna (nilotinib) for treatment of patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in chronic phase. The US Food & Drug Administration, Japan's Ministry of Health, Labour and Welfare and Swissmedic had previously approved Tasigna in the first-line indication.